about phamatic company and capacity planning

1. Slide

5. Slide

6. Slide 2005 Most Admired Biotech Company

8. 1AVASTIN : drug for patients with previously untreated metastatic cancer of the colon or rectum Slide Overview Mission To be the leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. In 2003 Revenues : $3,300 million 79 % from product sales Net Income: $563 million In 2004 AVASTIN 1 was approved by FDA First nine months of 2004 sales of AVASTIN 15 % or $2,684,000 million TARCEVA & OMNITARG both drugs that Genentech promise to launch in the next year

9. Genentech Product Information (2001-2003) Slide ($ in millions)

13. Production Process Slide

14. Manufacturing Process Flow Chart (per Batch) Slide 2,000L 12,000L ( 0.75gm/L )

15. Slide Ultra Filtration Frozen Bulk Packaged Products

17. Slide

23. A model for all cancer indication Slide

24. Slide Capacity Planning Demand-upside Demand-Basecase Demand- Downside Sample Capacity Requirements Chart

25. Slide Plan Economic optimum a Total Product Demand (kilograms) Distribution of Possible Demand Scenerios

28. Plant Size and Design Slide

29. Conclusion Slide

30. Slide